A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 24 May 2018
At a glance
- Drugs Belimumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 17 May 2018 Planned End Date changed from 30 Apr 2021 to 16 Apr 2021.
- 17 May 2018 Planned primary completion date changed from 30 Nov 2019 to 16 Nov 2019.
- 17 May 2018 Status changed from not yet recruiting to recruiting.